Company Information
CIN
Status
Date of Incorporation
10 November 2000
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
29 September 2023
Paid Up Capital
2,100,000
Authorised Capital
4,550,000
Directors
Manvitha Chennuru
Director/Designated Partner
about 2 years ago
about 2 years ago
Sri Lakshmi Chennuru
Director/Designated Partner
over 2 years ago
over 2 years ago
Rakesh Reddy Chennuru
Additional Director
over 5 years ago
over 5 years ago
Kanumuri Sri Lakshmi Soma Satya Sita Rama Raju
Director
over 18 years ago
over 18 years ago
Past Directors
Venu Gopal Reddy Bommireddy
Director
over 18 years ago
over 18 years ago
Patents
This invention relates to LY6G6F, VSIG10, TMEM25 and LSR proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble LY6G6F, VSIG10, TMEM25 and LSR molecules, extracellular domains ...
This invention relates to antibodies and antigen binding fragments and conjugates containing same and/or alternative scaffolds specific for LSR molecules which are suitable drugs for immunotherapy and treatment of specific cancer.
This invention relates to C10RF32 specific antibodies antibody fragments alternative scaffolds conjugates and compositions comprising same for treatment of cancer.
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagno...
This invention relates to a novel target for production of immune and non-immune based
therapeutics and for disease diagNOsis. More particμlarly, the invention provides
therapeutics antibothes against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154
antigens, which are differentially expressed in cancer, and diagNOst...
The present invention is directed to anti PVRIG antibodies and methods of using same.
Anti-PVRIG and anti-TIGIT antibodies are provided.
Anti-PVRIG, anti-TIGIT, and anti-PVRIG/anti-TIGIT bispecific antibodies are provided, as well as compositions, and methods of using the antibodies for the treatment of cancer.
ABSTRACT
“AN ANTI-PVRIG (POLIOVIRUS RECEPTOR RELATED LMMUNOGLOBULIN DOMAIN CONTAINING PROTEIN) ANTIBODY”
The present invention relates to an anti-PVRIG (Poliovirus Receptor Related lmmunoglobulin Domain Containing Protein) antibody, wherein said anti-PVRIG antibody comprises: the following vhCDR1, vhCDR2, vh...
The present invention is directed to anti-IL18-BP antibodies and uses thereof. The present invention is directed to monotherapy and combination treatments with for example immune checkpoint inhibitor antibodies, as described herein.
The present invention provides formulations comprising anti-TIGIT antibodies with CDRs identical to those shown in Figure 3 (i.e., CDRs identical to those for CPA.9.086.H4(S241P), as described herein.
Charges
29 August 2023
Others
0
29 August 2023
Others
0
29 August 2023
Others
0
Documents
Optional Attachment-(2)-30112020
Form DIR-12-30112020_signed
Evidence of cessation;-30112020
Optional Attachment-(1)-30112020
Notice of resignation;-30112020
Declaration of the appointee director, Managing director, in Form No. DIR-2;-30112020
Form INC-22-28082020_signed
Proof of Registered Office address(Conveyance/Lease deed/Rent Agreement along with the rent receipts) etc-27082020
Optional Attachment-(2)-27082020
Copies of the utility bills as mentioned above (not older than two months)-27082020
Copy of board resolution authorizing giving of notice-27082020
Optional Attachment-(1)-27082020
Optional Attachment-(1)-27082020
Form DIR-12-27082020_signed
Notice of resignation;-27082020
Declaration of the appointee director, Managing director, in Form No. DIR-2;-27082020
Evidence of cessation;-27082020
List of share holders, debenture holders;-12122019
Form MGT-7-12122019_signed
Directors report as per section 134(3)-26102019
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-26102019
Form AOC-4-26102019_signed
Form DPT-3-30062019
Form DPT-3-28062019
List of share holders, debenture holders;-27112018
Form MGT-7-27112018_signed
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-29102018
Directors report as per section 134(3)-29102018
Form AOC-4-29102018_signed
Copy of board resolution authorizing giving of notice-11082018
